These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 23624363

  • 1. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
    Jepsen MP, Jogdand PS, Singh SK, Esen M, Christiansen M, Issifou S, Hounkpatin AB, Ateba-Ngoa U, Kremsner PG, Dziegiel MH, Olesen-Larsen S, Jepsen S, Mordmüller B, Theisen M.
    J Infect Dis; 2013 Aug 01; 208(3):479-88. PubMed ID: 23624363
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G.
    Malar J; 2011 Dec 13; 10():359. PubMed ID: 22166048
    [Abstract] [Full Text] [Related]

  • 3. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
    Mamo H, Esen M, Ajua A, Theisen M, Mordmüller B, Petros B.
    Malar J; 2013 Feb 05; 12():51. PubMed ID: 23383869
    [Abstract] [Full Text] [Related]

  • 4. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
    Sirima SB, Mordmüller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, Tiono AB, Issifou S, Kaddumukasa M, Bangre O, Flach C, Christiansen M, Bang P, Chilengi R, Jepsen S, Kremsner PG, Theisen M, GMZ2 Trial Study Group.
    Vaccine; 2016 Aug 31; 34(38):4536-4542. PubMed ID: 27477844
    [Abstract] [Full Text] [Related]

  • 5. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate.
    Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M.
    Vaccine; 2011 Apr 12; 29(17):3284-92. PubMed ID: 21349366
    [Abstract] [Full Text] [Related]

  • 6. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
    Amoani B, Gyan B, Sakyi SA, Abu EK, Nuvor SV, Barnes P, Sarkodie-Addo T, Ahenkorah B, Sewor C, Dwomoh D, Theisen M, Cappello M, Wilson MD, Adu B.
    BMC Infect Dis; 2021 Apr 08; 21(1):332. PubMed ID: 33832450
    [Abstract] [Full Text] [Related]

  • 7. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
    Dejon-Agobe JC, Ateba-Ngoa U, Lalremruata A, Homoet A, Engelhorn J, Nouatin OP, Edoa JR, Fernandes JF, Esen M, Mouwenda YD, Betouke Ongwe EM, Massinga-Loembe M, Hoffman SL, Sim BKL, Theisen M, Kremsner PG, Adegnika AA, Lell B, Mordmüller B.
    Clin Infect Dis; 2019 Sep 27; 69(8):1377-1384. PubMed ID: 30561539
    [Abstract] [Full Text] [Related]

  • 8. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO, de Souza ABL, Riccio EKP, Bianco-Junior C, Totino PRR, Martins da Silva JH, Theisen M, Singh SK, Amoah LE, Ribeiro-Alves M, Souza RM, Lima-Junior JC, Daniel-Ribeiro CT, Pratt-Riccio LR.
    Malar J; 2022 Jan 04; 21(1):6. PubMed ID: 34983540
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate.
    Esen M, Kremsner PG, Schleucher R, Gässler M, Imoukhuede EB, Imbault N, Leroy O, Jepsen S, Knudsen BW, Schumm M, Knobloch J, Theisen M, Mordmüller B.
    Vaccine; 2009 Nov 16; 27(49):6862-8. PubMed ID: 19755144
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV, Biswas S, Pillai CR, Saxena RK.
    Vaccine; 2008 Aug 18; 26(35):4526-35. PubMed ID: 18590786
    [Abstract] [Full Text] [Related]

  • 11. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
    Bélard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Mürbeth RE, Milligan P, Imbault N, Imoukhuede EB, Theisen M, Jepsen S, Noor RA, Okech B, Kremsner PG, Mordmüller B.
    PLoS One; 2011 Aug 18; 6(7):e22525. PubMed ID: 21829466
    [Abstract] [Full Text] [Related]

  • 12. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
    Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, Bolad A, Berzins K, Corradin G, Leroy O, Theisen M, Sauerwein RW.
    Vaccine; 2007 Apr 12; 25(15):2930-40. PubMed ID: 16914240
    [Abstract] [Full Text] [Related]

  • 13. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
    Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, Stowers AW.
    J Infect Dis; 2002 Mar 01; 185(5):657-64. PubMed ID: 11865423
    [Abstract] [Full Text] [Related]

  • 14. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH, Singh SK, Nguyen TTTN, Roeffen W, Yang F, Lissau C, Madsen SM, Vrang A, Tiendrebeogo RW, Kana IH, Sauerwein RW, Theisen M, Rand KD.
    Pharm Res; 2017 Sep 01; 34(9):1970-1983. PubMed ID: 28646324
    [Abstract] [Full Text] [Related]

  • 15. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
    Baldwin SL, Roeffen W, Singh SK, Tiendrebeogo RW, Christiansen M, Beebe E, Carter D, Fox CB, Howard RF, Reed SG, Sauerwein R, Theisen M.
    Vaccine; 2016 Apr 27; 34(19):2207-15. PubMed ID: 26994314
    [Abstract] [Full Text] [Related]

  • 16. Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2.
    Nouatin O, Mengue JB, Dejon-Agobé JC, Fendel R, Ibáñez J, Ngoa UA, Edoa JR, Adégbité BR, Honkpéhédji YJ, Zinsou JF, Hounkpatin AB, Moutairou K, Homoet A, Esen M, Kreidenweiss A, Hoffman SL, Theisen M, Luty AJF, Lell B, Agnandji ST, Mombo-Ngoma G, Ramharter M, Kremsner P, Mordmüller B, Adegnika AA.
    PLoS Negl Trop Dis; 2021 Jun 27; 15(6):e0009361. PubMed ID: 34061838
    [Abstract] [Full Text] [Related]

  • 17. The GMZ2 malaria vaccine: from concept to efficacy in humans.
    Theisen M, Adu B, Mordmüller B, Singh S.
    Expert Rev Vaccines; 2017 Sep 27; 16(9):907-917. PubMed ID: 28699823
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.
    Mordmüller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, Mürbeth RE, Chilengi R, Noor R, Kilama WL, Imoukhuede EB, Imbault N, Leroy O, Theisen M, Jepsen S, Milligan P, Fendel R, Kremsner PG, Issifou S.
    Vaccine; 2010 Sep 24; 28(41):6698-703. PubMed ID: 20696154
    [Abstract] [Full Text] [Related]

  • 19. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.
    Vaccine; 2010 Apr 01; 28(16):2818-26. PubMed ID: 20170765
    [Abstract] [Full Text] [Related]

  • 20. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG.
    Vaccine; 2010 Jul 12; 28(31):5135-44. PubMed ID: 19737527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.